IDEXX Laboratories, Inc. $IDXX Stock: Titan Investment Management LLC Increases Stake

Posted by Geri Gentry on Oct 23rd, 2026

Titan Investment Management LLC lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 56.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,205 shares of the company’s stock after purchasing an additional 1,509 shares during the quarter. IDEXX Laboratories accounts for about 1.6% of Titan Investment Management LLC’s portfolio, making the stock its 22nd biggest position. Titan Investment Management LLC’s holdings in IDEXX Laboratories were worth $2,196,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IDXX. Bank of New York Mellon Corp acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $628,223,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in IDEXX Laboratories by 4.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 911,489 shares of the company’s stock worth $479,844,000 after buying an additional 39,700 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after buying an additional 288,471 shares during the period. Dimensional Fund Advisors LP raised its holdings in IDEXX Laboratories by 4.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 573,332 shares of the company’s stock worth $322,145,000 after buying an additional 23,582 shares during the period. Finally, Alyeska Investment Group L.P. lifted its stake in IDEXX Laboratories by 97.3% in the second quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after buying an additional 197,808 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company’s stock, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on IDXX shares. UBS Group upped their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. KeyCorp started coverage on shares of IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating on the stock. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday, October 16th. Finally, Barclays reduced their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Seven investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $744.09.

Check Out Our Latest Analysis on IDEXX Laboratories

IDEXX Laboratories Trading Up 2.4%

NASDAQ:IDXX opened at $566.76 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $532.51 and a two-hundred day moving average price of $551.58. The company has a market cap of $44.65 billion, a P/E ratio of 39.86, a price-to-earnings-growth ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the firm posted $3.50 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.